A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses

Antiviral Therapy

Volumn 17, Issue 7, 2012, Pages 1301-1309

  Lichtenstein, Kenneth A ^a   Armon, Carl ^b   Nagabhushanam, Vijaya ^a   Efaw, Benjamin J ^a   Frazer Abel, Ashley ^a   Hiserote, Melissa E ^a   Alam, Rafeul ^a  

^a DEPARTMENT OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NEF PROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; POL PROTEIN; RALTEGRAVIR; RANTES; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; VIRUS ENVELOPE PROTEIN;

ADULT; AGED; ARTICLE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MALE; MEMORY CELL; PILOT STUDY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL5; DISEASE PROGRESSION; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; INFLAMMATION; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PILOT PROJECTS; PYRROLIDINONES; VIRAL LOAD;

EID: 84870501232     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2350     Document Type: Article

References (29)

1. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T-lymphocyte activation than with plasma virus burden or virus chemokine co-receptor usage. J Infect Dis 1999; 179:859-870.
2. Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group Protocol 384. Clin Infect Dis 2009; 48:350-361.
3. Espert L, Denizot M, Grimaldi M, et al. Autophagy is involved in T-cell death after binding of HIV-1 envelope proteins to CXCR4. J Clin Invest 2006; 116:2161-2172.
4. + T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004; 2:e20.
5. Sousa AE, Carneiro J, Meierl-Schellersheim M, Grossman Z, Victorino RMM. CD4 T-cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immun 2002; 169:3400-3406.
6. + T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med 2002; 8:319-323.
7. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506-512.
8. Currier JS, Lundgren JE, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008; 118:e29-e35.
9. Hansson GK. Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
10. Keswani SC, Pardo CA, Cherry CL, Hoke A, McArthur JC. HIV-associated sensory neuropathies. AIDS 2002; 16:2105-2117.
11. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 2004; 38:743-753.
12. 3does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr 2008; 47:27-35.
13. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32:48-56.
14. Buzón MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-465.
15. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7; doi:10.1371/journal.pmed.1000321.
16. + T-cell response. J Infect Dis 2011; 203:960-968.
17. + T-cell losses using adjusted correlative analyses. AIDS 2000; 14:951-958.
18. Silvestri G, Feinberg MB. Turnover of lymphocytes and conceptual paradigms in HIV infection. J Clin Invest 2003; 112:821-824.
19. + T-cell depletion, and co-infection. J Infect Dis 2005; 191:694-701.
20. Mastroianni CM, Forcina G, d'Ettorre G, et al. Circulating levels of interleukin-7 in antiretroviral-naive and highly active antiretroviral therapy-treated HIV-infected patients. HIV Clin Trials 2001; 2:108-112.
21. +T-cells from HIV-1 infected individuals. Proc Natl Acad Sci U S A 2007; 104:2355-2360.
22. Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol 2001; 22:564-571.
23. Brieu N, Portales P, Carles M, Corbeau P. Interleukin-7 induces HIV type 1 R5 to X4 switch. Blood 2011; 117:2073-2074.
24. Lobritz M, Ratcliff A, Marozsan A, et al. Different mechanisms of HIV-1 inhibition by CCR5 agonists/antagonists (maraviroc, TAK-779 and PSC-RANTES) are linked to different drug resistance mechanisms. Antivir Ther 2009; 14 Suppl 1:A14.
25. An P, Nelson GW, Wang L, et al. Modulating influence on HIV-AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A 2002;99:10002-10007.
26. Vangelista L, Longhi R, Tolazzi M, et al. Design of RANTES-derived peptides with enhanced HIV-inhibitory activity and derivation of resistant HIV-1 strains. Retrovirology 2005; 2 Suppl 1:P113.
27. Chuenchitra T, Wasi C, de Souza M, et al. Serum levels of MIP-1 beta and RANTES in HIV-1 subtype CRF01-AE infected patients with different rates of disease progression. Southeast Asian J Trop Med Public Health 2008; 39:856-862.
28. Suresh P, Wanch A. Chemokines and chemokine receptors in HIV infection: role in pathogenesis and therapeutics. J Postgrad Med 2006; 52:210-217.
29. Cognasse F, Hamzeh-Cognasse H, Berthet J, et al. Altered release of regulated upon activation, normal T-cell expressed and secreted protein from human, normal platelets: contribution of distinct HIV 1MN gp-41 peptides. XVIII International AIDS Conference. 18-23 July 2010, Vienna, Austria. Poster THPE0055.